BIOCON LIMITED. Intrinsic Value
BIOCON · Healthcare · Current price ₹399.95
Is BIOCON LIMITED. undervalued?
DocStoX estimates the fair value of BIOCON LIMITED. at ₹196 per share, versus the current market price of ₹400. That puts the stock about -50.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹183), Relative P/E (₹83), Graham floor (₹106), Analyst target (₹441). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹83 (bear) to ₹196 (base) to ₹441 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹400 versus an intrinsic value of ₹196, BIOCON LIMITED. currently offers -50.9% of negative margin (i.e. a premium).
More on BIOCON LIMITED.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.